<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article" xml:lang="en"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">BMC Musculoskelet Disord</journal-id><journal-id journal-id-type="iso-abbrev">BMC Musculoskelet Disord</journal-id><journal-title-group><journal-title>BMC Musculoskeletal Disorders</journal-title></journal-title-group><issn pub-type="epub">1471-2474</issn><publisher><publisher-name>BioMed Central</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">24885217</article-id><article-id pub-id-type="pmc">4059090</article-id><article-id pub-id-type="publisher-id">1471-2474-15-184</article-id><article-id pub-id-type="doi">10.1186/1471-2474-15-184</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Influence of antiTNF-alpha antibody treatment on fracture healing under chronic inflammation</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes" id="A1"><name><surname>Timmen</surname><given-names>Melanie</given-names></name><xref ref-type="aff" rid="I2">2</xref><email>Melanie.Timmen@ukmuenster.de</email></contrib><contrib contrib-type="author" id="A2"><name><surname>Hidding</surname><given-names>Heriburg</given-names></name><xref ref-type="aff" rid="I2">2</xref><email>Heriburg.Hidding@ukmuenster.de</email></contrib><contrib contrib-type="author" id="A3"><name><surname>Wiesk&#x000f6;tter</surname><given-names>Britta</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>Britta.Wieskoetter@ukmuenster.de</email></contrib><contrib contrib-type="author" id="A4"><name><surname>Baum</surname><given-names>Wolfgang</given-names></name><xref ref-type="aff" rid="I3">3</xref><email>wolfgang.baum@uk-erlangen.de</email></contrib><contrib contrib-type="author" id="A5"><name><surname>Pap</surname><given-names>Thomas</given-names></name><xref ref-type="aff" rid="I2">2</xref><email>thomas.pap@uni-muenster.de</email></contrib><contrib contrib-type="author" id="A6"><name><surname>Raschke</surname><given-names>Michael J</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>Michael.Raschke@ukmuenster.de</email></contrib><contrib contrib-type="author" id="A7"><name><surname>Schett</surname><given-names>Georg</given-names></name><xref ref-type="aff" rid="I3">3</xref><email>georg.schett@uk-erlangen.de</email></contrib><contrib contrib-type="author" id="A8"><name><surname>Zwerina</surname><given-names>Jochen</given-names></name><xref ref-type="aff" rid="I4">4</xref><email>jochen.zwerina@osteologie.at</email></contrib><contrib contrib-type="author" id="A9"><name><surname>Stange</surname><given-names>Richard</given-names></name><xref ref-type="aff" rid="I1">1</xref><xref ref-type="aff" rid="I2">2</xref><email>Richard.Stange@ukmuenster.de</email></contrib></contrib-group><aff id="I1"><label>1</label>Department of Trauma, Hand and Reconstructive Surgery, University Hospital Muenster, Muenster, Germany</aff><aff id="I2"><label>2</label>Institute for Experimental Muskuloskeletal Medicine IEMM, University Hospital Muenster, Muenster, Germany</aff><aff id="I3"><label>3</label>Department of Internal Medicine 3, Rheumatology and Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany</aff><aff id="I4"><label>4</label>Ludwig Boltzmann Institute of Osteology at the Hanusch Hospital of WGKK and AUVA Trauma Centre Meidling, 1st Medical Department, Hanusch Hospital, Vienna, Austria</aff><pub-date pub-type="collection"><year>2014</year></pub-date><pub-date pub-type="epub"><day>29</day><month>5</month><year>2014</year></pub-date><volume>15</volume><fpage>184</fpage><lpage>184</lpage><history><date date-type="received"><day>27</day><month>2</month><year>2014</year></date><date date-type="accepted"><day>16</day><month>5</month><year>2014</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2014 Timmen et al.; licensee BioMed Central Ltd.</copyright-statement><copyright-year>2014</copyright-year><copyright-holder>Timmen et al.; licensee BioMed Central Ltd.</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/4.0"><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0">http://creativecommons.org/licenses/by/4.0</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p></license></permissions><self-uri xlink:href="http://www.biomedcentral.com/1471-2474/15/184"/><abstract><sec><title>Background</title><p>The overexpression of tumor necrosis factor (TNF)-&#x003b1; leads to systemic as well as local loss of bone and cartilage and is also an important regulator during fracture healing. In this study, we investigate how TNF-&#x003b1; inhibition using a targeted monoclonal antibody affects fracture healing in a TNF-&#x003b1; driven animal model of human rheumatoid arthritis (RA) and elucidate the question whether enduring the anti TNF-&#x003b1; therapy after trauma is beneficial or not.</p></sec><sec><title>Methods</title><p>A standardized femur fracture was applied to wild type and human TNF-&#x003b1; transgenic mice (hTNFtg mice), which develop an RA-like chronic polyarthritis. hTNFtg animals were treated with anti-TNF antibody (Infliximab) during the fracture repair. Untreated animals served as controls. Fracture healing was evaluated after 14 and 28&#x000a0;days of treatment by clinical assessment, biomechanical testing and histomorphometry.</p></sec><sec><title>Results</title><p>High levels of TNF-&#x003b1; influence fracture healing negatively, lead to reduced cartilage and more soft tissue in the callus as well as decreased biomechanical bone stability. Blocking TNF-&#x003b1; in hTNFtg mice lead to similar biomechanical and histomorphometrical properties as in wild type.</p></sec><sec><title>Conclusions</title><p>High levels of TNF-&#x003b1; during chronic inflammation have a negative impact on fracture healing. Our data suggest that TNF-&#x003b1; inhibition by an anti-TNF antibody does not interfere with fracture healing.</p></sec></abstract><kwd-group><kwd>Anti-TNF&#x003b1;</kwd><kwd>Inflammation</kwd><kwd>Fracture healing</kwd><kwd>Rheumatoid arthritis</kwd><kwd>Treatment</kwd></kwd-group></article-meta></front><body><sec><title>Background</title><p>Inflammatory diseases such as rheumatoid arthritis (RA), do not only increase the risk of fractures [<xref ref-type="bibr" rid="B1">1</xref>,<xref ref-type="bibr" rid="B2">2</xref>] but may also impair fracture healing by delaying the process and leading to non-unions [<xref ref-type="bibr" rid="B3">3</xref>]. Tumor necrosis factor alpha (TNF-&#x003b1;) is one of the main trigger of chronic inflammation in rheumatoid arthritis [<xref ref-type="bibr" rid="B4">4</xref>]. TNF-&#x003b1; is also critical for the cause of systemic as well as local loss of bone and cartilage during the course of disease [<xref ref-type="bibr" rid="B5">5</xref>]. The use of TNF-&#x003b1; blocking antibodies ameliorates the symptoms of this disease [<xref ref-type="bibr" rid="B6">6</xref>]. For instance, treatment with Infliximab, a (chimeric) monoclonal TNF-&#x003b1; antibody, has reduced the symptoms of RA patients [<xref ref-type="bibr" rid="B7">7</xref>]. Moreover, TNF-blocking agents combine a strong anti-inflammatory potential leading to direct protection of bone and cartilage [<xref ref-type="bibr" rid="B8">8</xref>].</p><p>TNF-&#x003b1; is also an important regulator of fracture healing [<xref ref-type="bibr" rid="B9">9</xref>]. Aside from Interleukin (IL)-1, -6 and -11, TNF-&#x003b1; is active within the initial inflammatory phase of fracture healing in macrophages and other inflammatory cells, where it leads to neo-angiogenesis and induces osteogenic differentiation of mesenchymal stem cells. In the terminal remodeling phase of fracture healing, high expression of TNF-&#x003b1; and IL-1 activates osteoclasts which degrade the trabecular bone and osteoblasts which regenerate the lamellar bone [<xref ref-type="bibr" rid="B10">10</xref>]. Previous studies have demonstrated that lack of TNF-&#x003b1; signaling during fracture healing impairs callus remodeling [<xref ref-type="bibr" rid="B11">11</xref>]. Thus, the TNF-&#x003b1; receptor knockout mice show a delay in fracture healing caused by a retarded development of cartilage, followed by chondrocyte apoptosis and remodeling of mineralized cartilage in the late phase of fracture healing [<xref ref-type="bibr" rid="B12">12</xref>].</p><p>Therefore, TNF-&#x003b1; is an important mediator during different phases of fracture healing. However, the influence of TNF-&#x003b1; blockade, as in treatment of RA patients under chronic inflammatory conditions, is still unknown. A retrospective study of rheumatoid patients treated with TNF- &#x003b1; antagonists showed no decreased risk of fractures [<xref ref-type="bibr" rid="B13">13</xref>]. Since TNF-&#x003b1; antibody therapy is widely used for treatment of RA and chronic inflammation, the question remains, whether the therapy should be continued in the case of a fracture or should be suspended. Therefore, we investigated the influence of TNF-&#x003b1; inhibition on fracture healing in an established model of chronic murine rheumatoid/inflammatory arthritis.</p></sec><sec sec-type="methods"><title>Methods</title><sec><title>Mice and fracture model</title><p>Generation of heterozygous human tumor necrosis factor transgenic (hTNFtg) mice (strain Tg197) were described previously [<xref ref-type="bibr" rid="B14">14</xref>]. Homozygous hTNFtg mice develop a chronic inflammatory arthritis due to the overexpression of human TNF which is acting on the murine TNF receptor I. Disease starts at the age of 6&#x000a0;weeks and is accompanied by local and systemic bone loss reflecting inflammatory bone disease of human rheumatoid arthritis. We used 12&#x000a0;week old, female mice for the fracture experiments. Three groups of 20 mice, including wild type, hTNFtg untreated and hTNFtg treated with a (chimeric) antiTNF-&#x003b1; antibody (Infliximab, 10&#x000a0;mg/kg, 3 times weekly, Centocor, The Netherlands, TNFi) as described [<xref ref-type="bibr" rid="B15">15</xref>]. After anaesthesia using a ketamine hydrochloride/xylazine mixture (80 and 12&#x000a0;mg/kg body weight, i.p.) the left leg was fractured with three point bending. It was stabilized with an intramedullary nail (hollow needle 23G) [<xref ref-type="bibr" rid="B16">16</xref>] (see also Figure&#x000a0;<xref ref-type="fig" rid="F1">1</xref>). Carprofen (4&#x000a0;mg/kg intra muscular) was given as an analgesic and further on at 24&#x000a0;hour intervals when required. Mice were euthanized by cervical dislocation 14 or 28&#x000a0;days after surgery. All experiments were performed according to the protocol approved by the Animal Care and Use Committee of the University Hospital Erlangen, Germany.</p><fig id="F1" position="float"><label>Figure 1</label><caption><p><bold>Radiographs of a fractured femur after surgery OP (A) and after 28 days of healing (B).</bold> Mouse femur fractured and stabilized by an intramedullary nail (Schmidmaier <italic>et al.</italic>, [<xref ref-type="bibr" rid="B18">18</xref>], modified).</p></caption><graphic xlink:href="1471-2474-15-184-1"/></fig></sec><sec><title>Biomechanical analyses</title><p>For biomechanical analyses, mice (n&#x02009;=&#x02009;10, each wild type, hTNFtg or hTNFtg treated with Infliximab) were euthanized 28&#x000a0;days after surgery. Both femurs were dissected and prepared for biomechanical testing as described previously [<xref ref-type="bibr" rid="B17">17</xref>,<xref ref-type="bibr" rid="B18">18</xref>]. Briefly, the proximal and distal ends of each femur were embedded into two molds with bone cement (Palacos R, Heraeus Kulzer GmbH, Germany). Each mold was then connected to a pivoted axis. A linear constant feed rate, generated by a material testing machine (LR5Kplus, Lloyd Instruments, Meerbusch, Germany), was loaded by a lever attached to one of the pivoted axes. The bone was preloaded at an axial force of 5&#x000a0;N and a constant linear propulsion (v&#x02009;=&#x02009;1&#x000a0;mm/min) was applied by the testing machine. The translation of the material testing machine was transformed to an uniform torsional movement. The free axis was connected to a strain-gauge (<italic>F</italic><sub>max</sub>&#x02009;=&#x02009;250&#x000a0;N, XLC, Lloyd Instruments, Meerbusch, Germany) that detected the torsional force. The data were recorded using Catman32 software (HBM, Darmstadt, Germany) and analyzed by Microsoft Excel (Redmont, USA). The angle of failure and the maximum load were determined as material characteristics and the torsional stiffness (N/&#x000b0;) was calculated as a biomechanical parameter. Each parameter was compared with the values of the non-fractured contralateral femur (ratio of fractured/non-fractured femur (100%)). Data shown are medians with a range of up to 8 measurements for each group.</p></sec><sec><title>Histomorphometry</title><p>For histomorphological analyses fractured femurs (n&#x02009;=&#x02009;10, each group) were embedded undecalcified in methylmethacrylate (Technovit&#x000ae; 9100, Heraeus, Germany). Sagittal serial sections (5&#x000a0;&#x003bc;m) were stained with alcian blue. Image Pro Plus software (ImagePro&#x000ae;Plus 7.0, Media Cybernetics Inc., Bethesda, USA) was used to determine and calculate the following histological parameters within the area of interest (see also Figure&#x000a0;<xref ref-type="fig" rid="F2">2</xref>A): whole callus area (black line, cartilage area (dotted line)/total callus area and area of soft tissue (dashed line)/total callus area. The histological analysis was performed randomized and blinded with regard to genotype and treatment. Complicated fractures were excluded from the analysis. The data shown are means with SD of up to10 measurements of each group.</p><fig id="F2" position="float"><label>Figure 2</label><caption><p><bold>Histological analysis of the fracture callus composition 14 and 28&#x000a0;days after surgery.</bold> Alcian blue staining was performed using sagittal section of the fractured femur. Using digital image analysis, the area of different tissues was determined within the whole callus as indicated in <bold>A</bold>. Overview of the tissue composition of a sagittal section of a fractured femur: Area of whole callus, black line; cartilage area, dotted line; soft tissue, dashed line. <bold>B</bold>: Comparison of the callus composition after 14 and 28&#x000a0;days with wild type, hTNFtg and hTNFtg&#x02009;+&#x02009;TNFi group within the site of fracture (AOI) after Alcian blue staining (representative pictures, scale bar 500&#x000a0;&#x003bc;m).</p></caption><graphic xlink:href="1471-2474-15-184-2"/></fig></sec><sec><title>Statistic</title><p>Statistical analysis (Mann&#x02013;Whitney-U-test: conducted between each group, non-parametric, two tailed, Confidence Interval: 95%) was carried out using GraphPad Prism 5.02 (GraphPad Software, San Diego, USA). p-values &#x0003e;0.05 were regarded as significant, p-values between 0.05 and 0.1 indicate tendency.</p></sec></sec><sec sec-type="results"><title>Results</title><sec><title>Clinical assessment</title><p>As described previously, the hTNFtg mice are smaller in size and weight compared to their wild type littermates [<xref ref-type="bibr" rid="B14">14</xref>,<xref ref-type="bibr" rid="B19">19</xref>]. A treatment of these mice with a human anti-TNF antibody prevents the development of an inflammatory polyarthritis [<xref ref-type="bibr" rid="B14">14</xref>]. In our study, we used hTNFtg mice at the age of 12&#x000a0;weeks for surgery and monitored the follow-up of the healing process for up to 4&#x000a0;weeks. However, the animals were smaller compared to wild type mice. This influenced the outcome of fracturing and therefore the progression of fracture healing. As shown by radiographic and histological pictures, some fractures occurred near the knee joint or were dislocated or fragmentary, and were therefore excluded from further analyses.</p></sec><sec><title>Biomechanical bone stability after fracture</title><p>Two different material characteristics were measured, that are influenced by the tissue composition during fracture healing. Firstly, the force that is needed to break the bone, characterized by maximum torque, as well the angle of failure that is used as a parameter of the flexibility of the bone, were measured. Secondly, the torsional stiffness was calculated from these values as a measure for the biomechanical stability of the bone. After 28&#x000a0;days of healing there was no significant difference in the maximum torque between the wild type group and both hTNFtg groups, although the standard deviation was high in the hTNFtg group without treatment (Figure&#x000a0;<xref ref-type="fig" rid="F3">3</xref>). The fractured femur yield almost 100% of the maximum torque measured for the unfractured femur in all groups (wild type: 89%, hTNFtg: 99.5%, hTNFtg&#x02009;+&#x02009;TNFi: 69%). Interestingly, the angle of failure in the wild type group (128%) was comparable to the hTNFtg&#x02009;+&#x02009;TNFi group (98%), but significantly increased in the hTNFtg group (221%, wild type vs. hTNFtg: p&#x02009;=&#x02009;0.0293; hTNFtg vs. hTNFtg&#x02009;+&#x02009;TNFi: p&#x02009;=&#x02009;0.014). The torsional stiffness, however, was not significantly altered in the hTNFtg group (69.3%) compared to both wild type (91.3%) and the TNFi treated hTNFtg group (96%) (wild type vs. hTNFtg: p&#x02009;=&#x02009;0.345; hTNFtg vs hTNFtg&#x02009;+&#x02009;TNFi: p&#x02009;=&#x02009;0.617).</p><fig id="F3" position="float"><label>Figure 3</label><caption><p><bold>Biomechanical analysis of the fractured femur.</bold> Torsional testing was applied to the fractured and unfractured femur of each animal. Maximum torque [Nmm] and angle of failure [&#x000b0;] were determined and used for calculation of torsional stiffness [Nmm/&#x000b0;]. The ratio of fractured femur/non-fractured femur [%] was calculated. Wild type: n&#x02009;=&#x02009;8, hTNFtg: n&#x02009;=&#x02009;6, hTNFtg&#x02009;+&#x02009;TNFi: n&#x02009;=&#x02009;7, * p&#x02009;&#x0003c;&#x02009;0.05; dashed line: p&#x02009;&#x0003c;&#x02009;0.1, tendency.</p></caption><graphic xlink:href="1471-2474-15-184-3"/></fig></sec><sec><title>Histomorphological analysis of fracture callus composition after 14 and 28&#x000a0;days of healing</title><p>Further investigation of the callus tissue composition provided an indication for the altered biomechanical properties of the three different groups. Sagittal sections of femurs were stained for cartilage using alcian blue staining and for determination of the whole callus area (Figure&#x000a0;<xref ref-type="fig" rid="F2">2</xref>A). The area of cartilage (stained in blue; dotted line) and the area of soft tissue (dashed line) were compared in the callus area. These parameters change the most within the investigated time points at day 14 and day 28 (Figure&#x000a0;<xref ref-type="fig" rid="F2">2</xref>). The quantitative analysis of all fracture calli showed a significantly bigger callus area in the hTNFtg and hTNFtg&#x02009;+&#x02009;TNFi treated groups compared to the wild type group after 14&#x000a0;days (37%, Figure&#x000a0;<xref ref-type="fig" rid="F4">4</xref>A) and 28&#x000a0;days (30%, Figure&#x000a0;<xref ref-type="fig" rid="F4">4</xref>D). Further investigation of the composition surrounding the fracture site revealed an increased area of soft tissue in the hTNFtg group (24.1% vs. 11.4% (wild type, p&#x02009;=&#x02009;0.0307) and 18.7% (hTNFtg&#x02009;+&#x02009;TNFi) compared to the wild type at day 14 (Figure&#x000a0;<xref ref-type="fig" rid="F4">4</xref>B). Additionally, the hTNFtg&#x02009;+&#x02009;TNFi group displayed twice as much cartilage than both other groups on day 14 (18.4% vs 9.9% in wild type (p&#x02009;=&#x02009;0.0234) or 7.6% in hTNFtg (p&#x02009;=&#x02009;0.0159) (Figure&#x000a0;<xref ref-type="fig" rid="F4">4</xref>C). After 28&#x000a0;days the content of soft tissue was higher within the wild type group (5.8% vs. 2.5% in wild type and 2% in hTNFtg&#x02009;+&#x02009;TNFi; p&#x02009;&#x0003c;&#x02009;0.1). The amount of cartilage in wild type and hTNFtg&#x02009;+&#x02009;TNFi group was lower (0.8%) compared to 14&#x000a0;days, but much less in hTNFtg without treatment (0.18%) (Figure&#x000a0;<xref ref-type="fig" rid="F4">4</xref>B). Furthermore, the area of mineralized bone (trabecular bone within the callus area) was determined, but there were no differences within the three groups (Data not shown).</p><fig id="F4" position="float"><label>Figure 4</label><caption><p><bold>Quantification of the callus composition after 14 and 28&#x000a0;days of fracture healing using digital image analysis. A/D</bold>: Whole callus area was determined [mm<sup>2</sup>]. Area of soft tissue <bold>(B/E)</bold> as well as Cartilage area <bold>(C/F)</bold> were measured as depicted in Figure&#x000a0;<xref ref-type="fig" rid="F3">3</xref>A and displayed as a ratio to the whole callus area [%]. Wild type: n&#x02009;=&#x02009;10; hTNFtg: n&#x02009;=&#x02009;5; hTNFtg&#x02009;+&#x02009;TNFi: n&#x02009;=&#x02009;7, * p&#x02009;&#x0003c;&#x02009;0.05, dashed line p&#x02009;&#x0003c;&#x02009;0.1, tendency.</p></caption><graphic xlink:href="1471-2474-15-184-4"/></fig></sec></sec><sec sec-type="discussion"><title>Discussion</title><p>The hTNFtg mouse is considered to be a valuable model of human RA [<xref ref-type="bibr" rid="B19">19</xref>,<xref ref-type="bibr" rid="B20">20</xref>]. In these animals, overexpression of human TNF-&#x003b1; induces severe inflammatory polyarthritis. This arthritis shares many hallmarks with the human counterpart, such as polyarticular involvement of the small joints, chronic and progressive course of disease, and the destruction of cartilage and subchondral bone. The disease is driven by the overexpression of proinflammatory cytokines. The overexpression of TNF-&#x003b1; was described as being responsible for a dramatic loss of trabecular bone and, to a lesser extent, cortical bone [<xref ref-type="bibr" rid="B20">20</xref>]. The influence of a chronic inflammation on fracture healing, however, has not been studied. Therefore, we used hTNFtg animals, with high systemic levels of TNF-&#x003b1; to investigate its influence on the composition of the fracture callus and the progression of the healing process.</p><p>The importance of TNF-&#x003b1; signaling during fracture healing is commonly accepted today. On the one hand, it is known that TNF-&#x003b1; expression increases soon after injury [<xref ref-type="bibr" rid="B11">11</xref>,<xref ref-type="bibr" rid="B21">21</xref>]. During this inflammatory phase different cell types, including mesenchymal stem cells, located in the surrounding tissue, are recruited to the fracture site and initiate the formation of the primary callus. Different studies were able to demonstrate that deficiency of TNF-&#x003b1; signaling causes a delay in callus remodeling with regard to chondrocyte maturation and apoptosis in the later phases of fracture healing [<xref ref-type="bibr" rid="B11">11</xref>,<xref ref-type="bibr" rid="B12">12</xref>,<xref ref-type="bibr" rid="B22">22</xref>]. On the other hand, high levels of TNF-&#x003b1; contribute to accelerated loss of cartilage during fracture healing as seen in diabetic mice [<xref ref-type="bibr" rid="B23">23</xref>]. In our study we have demonstrated that high systemic levels of TNF-&#x003b1; influence the biomechanical stability and composition of the bone in the course of fracture healing, lead to increased callus formation with less cartilage and more soft tissue within the fracture gap. These alterations of the callus composition resulted in lowered biomechanical stability with a higher flexibility of bone within the callus after 28&#x000a0;days of healing. Histologically, we found that the callus of hTNFtg animals was built of less cartilage and more soft tissue compared to the wild type which leads to an altered stability of the callus. Therefore, our results indicate a negative influence of chronically elevated TNF-&#x003b1; level during the fracture healing process.</p><p>TNF-&#x003b1;-inhibitors like Infliximab are used in treatment of rheumatic patients to bind TNF-&#x003b1; with high affinity to reduce inflammatory symptoms [<xref ref-type="bibr" rid="B6">6</xref>,<xref ref-type="bibr" rid="B24">24</xref>]. The high efficiency of the blocking hTNF antibody was proven within the hTNFtg animal model [<xref ref-type="bibr" rid="B14">14</xref>]. Treated animals do not show any signs of rheumatoid like disease. The influence of a TNF-&#x003b1;-inhibitor on fracture healing, however, has been investigated in a wild type rat model under non-inflammatory conditions. In this case the authors did not find any impairment of metaphysal bone healing [<xref ref-type="bibr" rid="B25">25</xref>]. Under chronic inflammatory conditions, as it was shown in this study, the blockade of TNF-&#x003b1; during fracture healing (by Infliximab treatment) led to an increased callus size, which was accompanied by an increase in cartilage tissue compared to the not treated group. After 28&#x000a0;days of fracture healing, the fracture callus composition resembled the wild type situation. Biomechanical testing revealed no differences compared to wild type fracture healing. Treatment with Infliximab even seemed to compensate the derogating effects of elevated systemic TNF-&#x003b1; levels on fracture healing which can be concluded from the similarity of the biomechanical and histological results of the TNFi treated group compared to wild type in our model. It might be interesting to further distinguish between the negative effects of pathologically elevated levels of TNF-&#x003b1; and the positive effects of endogenous TNF signaling during fracture healing. This could be done by performing studies using the fracture model and dose dependent treatment with hTNF blocking antibody and to look for the onset of callus development and callus composition in the course of healing. Our results provide indication that rheumatoid arthritis patients, who sustained a fracture during the treatment with TNF-&#x003b1; antagonist, should continue this therapy.</p></sec><sec sec-type="conclusions"><title>Conclusion</title><p>Elevated TNF-&#x003b1; level have a negative impact on the physiological development of the callus and thereby impair fracture healing in this murine model of chronic inflammation. We have found that the treatment of this chronic inflammation during fracture healing is beneficial and restores the biomechanical and morphological condition as found in the wild type. Further studies on fracture healing under chronic inflammatory conditions in animal models and rheumatoid arthritis patients will be necessary to further elucidate the mechanisms of this positive effect of anti-TNF&#x003b1;-treatment.</p></sec><sec><title>Abbreviations</title><p>TNF-&#x003b1;: Tumor necrosis factor alpha; RA: Rheumatoid arthritis; hTNFtg: Mice with a human TNF alpha transgenic background; IL: Interleukin; TNFi: AntiTNFalpha antibody treatment; MSC: Mesenchymal stem cell; AOI: Area of interest.</p></sec><sec><title>Competing interests</title><p>The authors declare that they have no competing interests.</p></sec><sec><title>Authors&#x02019; contributions</title><p>MT, WB, HH, BW and RS collected the data. RS, TP and JZ designed the study. TP, MR and GS contributed to the data analysis and interpretation. MT, RS and JZ wrote the manuscript. All authors read and approved the final manuscript.</p></sec><sec><title>Pre-publication history</title><p>The pre-publication history for this paper can be accessed here:</p><p><ext-link ext-link-type="uri" xlink:href="http://www.biomedcentral.com/1471-2474/15/184/prepub">http://www.biomedcentral.com/1471-2474/15/184/prepub</ext-link></p></sec></body><back><sec><title>Acknowledgements</title><p>We thank Simone Niehues and Iska Leifert for excellent technical assistance.</p><p>We acknowledge support by Deutsche Forschungsgemeinschaft and Open Access Publication Fund of University of Muenster.</p><sec><title>Funding</title><p>This project was funded by the ELAN Fonds of the University of Erlangen-Nuremberg (J.Z.).</p></sec></sec><ref-list><ref id="B1"><mixed-citation publication-type="journal"><name><surname>Abdulghani</surname><given-names>S</given-names></name><name><surname>Caetano-Lopes</surname><given-names>J</given-names></name><name><surname>Canhao</surname><given-names>H</given-names></name><name><surname>Fonseca</surname><given-names>JE</given-names></name><article-title>Biomechanical effects of inflammatory diseases on bone-rheumatoid arthritis as a paradigm</article-title><source>Autoimmun Rev</source><year>2009</year><volume>8</volume><issue>8</issue><fpage>668</fpage><lpage>671</lpage><pub-id pub-id-type="doi">10.1016/j.autrev.2009.02.021</pub-id><pub-id pub-id-type="pmid">19223022</pub-id></mixed-citation></ref><ref id="B2"><mixed-citation publication-type="journal"><name><surname>Bogoch</surname><given-names>ER</given-names></name><name><surname>Moran</surname><given-names>E</given-names></name><article-title>Abnormal bone remodelling in inflammatory arthritis</article-title><source>Can J Surg</source><year>1998</year><volume>41</volume><issue>4</issue><fpage>264</fpage><lpage>271</lpage><pub-id pub-id-type="pmid">9711159</pub-id></mixed-citation></ref><ref id="B3"><mixed-citation publication-type="journal"><name><surname>Claes</surname><given-names>L</given-names></name><name><surname>Recknagel</surname><given-names>S</given-names></name><name><surname>Ignatius</surname><given-names>A</given-names></name><article-title>Fracture healing under healthy and inflammatory conditions</article-title><source>Nat Rev Rheumatol</source><year>2012</year><volume>8</volume><issue>3</issue><fpage>133</fpage><lpage>143</lpage><pub-id pub-id-type="doi">10.1038/nrrheum.2012.1</pub-id><pub-id pub-id-type="pmid">22293759</pub-id></mixed-citation></ref><ref id="B4"><mixed-citation publication-type="journal"><name><surname>McInnes</surname><given-names>IB</given-names></name><name><surname>Schett</surname><given-names>G</given-names></name><article-title>The pathogenesis of rheumatoid arthritis</article-title><source>N Engl J Med</source><year>2011</year><volume>365</volume><issue>23</issue><fpage>2205</fpage><lpage>2219</lpage><pub-id pub-id-type="doi">10.1056/NEJMra1004965</pub-id><pub-id pub-id-type="pmid">22150039</pub-id></mixed-citation></ref><ref id="B5"><mixed-citation publication-type="journal"><name><surname>Schett</surname><given-names>G</given-names></name><article-title>Effects of inflammatory and anti-inflammatory cytokines on the bone</article-title><source>Eur J Clin Invest</source><year>2011</year><volume>41</volume><issue>12</issue><fpage>1361</fpage><lpage>1366</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2362.2011.02545.x</pub-id><pub-id pub-id-type="pmid">21615394</pub-id></mixed-citation></ref><ref id="B6"><mixed-citation publication-type="journal"><name><surname>Tracey</surname><given-names>D</given-names></name><name><surname>Klareskog</surname><given-names>L</given-names></name><name><surname>Sasso</surname><given-names>EH</given-names></name><name><surname>Salfeld</surname><given-names>JG</given-names></name><name><surname>Tak</surname><given-names>PP</given-names></name><article-title>Tumor necrosis factor antagonist mechanisms of action: a comprehensive review</article-title><source>Pharmacol Ther</source><year>2008</year><volume>117</volume><issue>2</issue><fpage>244</fpage><lpage>279</lpage><pub-id pub-id-type="doi">10.1016/j.pharmthera.2007.10.001</pub-id><pub-id pub-id-type="pmid">18155297</pub-id></mixed-citation></ref><ref id="B7"><mixed-citation publication-type="journal"><name><surname>Elliott</surname><given-names>MJ</given-names></name><name><surname>Maini</surname><given-names>RN</given-names></name><name><surname>Feldmann</surname><given-names>M</given-names></name><name><surname>Kalden</surname><given-names>JR</given-names></name><name><surname>Antoni</surname><given-names>C</given-names></name><name><surname>Smolen</surname><given-names>JS</given-names></name><name><surname>Leeb</surname><given-names>B</given-names></name><name><surname>Breedveld</surname><given-names>FC</given-names></name><name><surname>Macfarlane</surname><given-names>JD</given-names></name><name><surname>Bijl</surname><given-names>H</given-names></name><name><surname>Woody</surname><given-names>JN</given-names></name><article-title>Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis</article-title><source>Lancet</source><year>1994</year><volume>344</volume><issue>8930</issue><fpage>1105</fpage><lpage>1110</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(94)90628-9</pub-id><pub-id pub-id-type="pmid">7934491</pub-id></mixed-citation></ref><ref id="B8"><mixed-citation publication-type="journal"><name><surname>Schett</surname><given-names>G</given-names></name><name><surname>Coates</surname><given-names>LC</given-names></name><name><surname>Ash</surname><given-names>ZR</given-names></name><name><surname>Finzel</surname><given-names>S</given-names></name><name><surname>Conaghan</surname><given-names>PG</given-names></name><article-title>Structural damage in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: traditional views, novel insights gained from TNF blockade, and concepts for the future</article-title><source>Arthritis Res Ther</source><year>2011</year><volume>13</volume><issue>Suppl 1</issue><fpage>S4</fpage><pub-id pub-id-type="pmid">21624183</pub-id></mixed-citation></ref><ref id="B9"><mixed-citation publication-type="journal"><name><surname>Kon</surname><given-names>T</given-names></name><name><surname>Cho</surname><given-names>TJ</given-names></name><name><surname>Aizawa</surname><given-names>T</given-names></name><name><surname>Yamazaki</surname><given-names>M</given-names></name><name><surname>Nooh</surname><given-names>N</given-names></name><name><surname>Graves</surname><given-names>D</given-names></name><name><surname>Gerstenfeld</surname><given-names>LC</given-names></name><name><surname>Einhorn</surname><given-names>TA</given-names></name><article-title>Expression of osteoprotegerin, receptor activator of NF-kappaB ligand (osteoprotegerin ligand) and related proinflammatory cytokines during fracture healing</article-title><source>J Bone Miner Res</source><year>2001</year><volume>16</volume><issue>6</issue><fpage>1004</fpage><lpage>1014</lpage><pub-id pub-id-type="doi">10.1359/jbmr.2001.16.6.1004</pub-id><pub-id pub-id-type="pmid">11393777</pub-id></mixed-citation></ref><ref id="B10"><mixed-citation publication-type="journal"><name><surname>Marsell</surname><given-names>R</given-names></name><name><surname>Einhorn</surname><given-names>TA</given-names></name><article-title>The biology of fracture healing</article-title><source>Injury</source><year>2011</year><volume>42</volume><issue>6</issue><fpage>551</fpage><lpage>555</lpage><pub-id pub-id-type="doi">10.1016/j.injury.2011.03.031</pub-id><pub-id pub-id-type="pmid">21489527</pub-id></mixed-citation></ref><ref id="B11"><mixed-citation publication-type="journal"><name><surname>Gerstenfeld</surname><given-names>LC</given-names></name><name><surname>Cho</surname><given-names>TJ</given-names></name><name><surname>Kon</surname><given-names>T</given-names></name><name><surname>Aizawa</surname><given-names>T</given-names></name><name><surname>Cruceta</surname><given-names>J</given-names></name><name><surname>Graves</surname><given-names>BD</given-names></name><name><surname>Einhorn</surname><given-names>TA</given-names></name><article-title>Impaired intramembranous bone formation during bone repair in the absence of tumor necrosis factor-alpha signaling</article-title><source>Cells Tissues Organs</source><year>2001</year><volume>169</volume><issue>3</issue><fpage>285</fpage><lpage>294</lpage><pub-id pub-id-type="doi">10.1159/000047893</pub-id><pub-id pub-id-type="pmid">11455125</pub-id></mixed-citation></ref><ref id="B12"><mixed-citation publication-type="journal"><name><surname>Gerstenfeld</surname><given-names>LC</given-names></name><name><surname>Cho</surname><given-names>TJ</given-names></name><name><surname>Kon</surname><given-names>T</given-names></name><name><surname>Aizawa</surname><given-names>T</given-names></name><name><surname>Tsay</surname><given-names>A</given-names></name><name><surname>Fitch</surname><given-names>J</given-names></name><name><surname>Barnes</surname><given-names>GL</given-names></name><name><surname>Graves</surname><given-names>DT</given-names></name><name><surname>Einhorn</surname><given-names>TA</given-names></name><article-title>Impaired fracture healing in the absence of TNF-alpha signaling: the role of TNF-alpha in endochondral cartilage resorption</article-title><source>J Bone Miner Res</source><year>2003</year><volume>18</volume><issue>9</issue><fpage>1584</fpage><lpage>1592</lpage><pub-id pub-id-type="doi">10.1359/jbmr.2003.18.9.1584</pub-id><pub-id pub-id-type="pmid">12968667</pub-id></mixed-citation></ref><ref id="B13"><mixed-citation publication-type="journal"><name><surname>Kawai</surname><given-names>VK</given-names></name><name><surname>Grijalva</surname><given-names>CG</given-names></name><name><surname>Arbogast</surname><given-names>PG</given-names></name><name><surname>Curtis</surname><given-names>JR</given-names></name><name><surname>Solomon</surname><given-names>DH</given-names></name><name><surname>Delzell</surname><given-names>E</given-names></name><name><surname>Chen</surname><given-names>L</given-names></name><name><surname>Ouellet-Hellstrom</surname><given-names>R</given-names></name><name><surname>Herrinton</surname><given-names>L</given-names></name><name><surname>Liu</surname><given-names>L</given-names></name><name><surname>Mitchell</surname><given-names>EF</given-names><suffix>Jr</suffix></name><name><surname>Stein</surname><given-names>CM</given-names></name><name><surname>Griffin</surname><given-names>MR</given-names></name><article-title>Initiation of tumor necrosis factor alpha antagonists and risk of fractures in patients with selected rheumatic and autoimmune diseases</article-title><source>Arthritis Care Res (Hoboken)</source><year>2013</year><volume>65</volume><issue>7</issue><fpage>1085</fpage><lpage>1094</lpage><pub-id pub-id-type="doi">10.1002/acr.21937</pub-id><pub-id pub-id-type="pmid">23281339</pub-id></mixed-citation></ref><ref id="B14"><mixed-citation publication-type="journal"><name><surname>Keffer</surname><given-names>J</given-names></name><name><surname>Probert</surname><given-names>L</given-names></name><name><surname>Cazlaris</surname><given-names>H</given-names></name><name><surname>Georgopoulos</surname><given-names>S</given-names></name><name><surname>Kaslaris</surname><given-names>E</given-names></name><name><surname>Kioussis</surname><given-names>D</given-names></name><name><surname>Kollias</surname><given-names>G</given-names></name><article-title>Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritis</article-title><source>EMBO J</source><year>1991</year><volume>10</volume><issue>13</issue><fpage>4025</fpage><lpage>4031</lpage><pub-id pub-id-type="pmid">1721867</pub-id></mixed-citation></ref><ref id="B15"><mixed-citation publication-type="journal"><name><surname>Zwerina</surname><given-names>J</given-names></name><name><surname>Hayer</surname><given-names>S</given-names></name><name><surname>Tohidast-Akrad</surname><given-names>M</given-names></name><name><surname>Bergmeister</surname><given-names>H</given-names></name><name><surname>Redlich</surname><given-names>K</given-names></name><name><surname>Feige</surname><given-names>U</given-names></name><name><surname>Dunstan</surname><given-names>C</given-names></name><name><surname>Kollias</surname><given-names>G</given-names></name><name><surname>Steiner</surname><given-names>G</given-names></name><name><surname>Smolen</surname><given-names>J</given-names></name><name><surname>Schett</surname><given-names>G</given-names></name><article-title>Single and combined inhibition of tumor necrosis factor, interleukin-1, and RANKL pathways in tumor necrosis factor-induced arthritis: effects on synovial inflammation, bone erosion, and cartilage destruction</article-title><source>Arthritis Rheum</source><year>2004</year><volume>50</volume><issue>1</issue><fpage>277</fpage><lpage>290</lpage><pub-id pub-id-type="doi">10.1002/art.11487</pub-id><pub-id pub-id-type="pmid">14730626</pub-id></mixed-citation></ref><ref id="B16"><mixed-citation publication-type="journal"><name><surname>Bertrand</surname><given-names>J</given-names></name><name><surname>Stange</surname><given-names>R</given-names></name><name><surname>Hidding</surname><given-names>H</given-names></name><name><surname>Echtermeyer</surname><given-names>F</given-names></name><name><surname>Nalesso</surname><given-names>G</given-names></name><name><surname>Godmann</surname><given-names>L</given-names></name><name><surname>Timmen</surname><given-names>M</given-names></name><name><surname>Bruckner</surname><given-names>P</given-names></name><name><surname>Dell&#x02019;Accio</surname><given-names>F</given-names></name><name><surname>Raschke</surname><given-names>MJ</given-names></name><name><surname>Pap</surname><given-names>T</given-names></name><name><surname>Dreier</surname><given-names>R</given-names></name><article-title>Syndecan 4 supports bone fracture repair, but not fetal skeletal development, in mice</article-title><source>Arthritis Rheum</source><year>2013</year><volume>65</volume><issue>3</issue><fpage>743</fpage><lpage>752</lpage><pub-id pub-id-type="doi">10.1002/art.37817</pub-id><pub-id pub-id-type="pmid">23233348</pub-id></mixed-citation></ref><ref id="B17"><mixed-citation publication-type="journal"><name><surname>Stange</surname><given-names>R</given-names></name><name><surname>Kronenberg</surname><given-names>D</given-names></name><name><surname>Timmen</surname><given-names>M</given-names></name><name><surname>Everding</surname><given-names>J</given-names></name><name><surname>Hidding</surname><given-names>H</given-names></name><name><surname>Eckes</surname><given-names>B</given-names></name><name><surname>Hansen</surname><given-names>U</given-names></name><name><surname>Holtkamp</surname><given-names>M</given-names></name><name><surname>Karst</surname><given-names>U</given-names></name><name><surname>Pap</surname><given-names>T</given-names></name><name><surname>Raschke</surname><given-names>MJ</given-names></name><article-title>Age-related bone deterioration is diminished by disrupted collagen sensing in integrin alpha2beta1 deficient mice</article-title><source>Bone</source><year>2013</year><volume>56</volume><issue>1</issue><fpage>48</fpage><lpage>54</lpage><pub-id pub-id-type="doi">10.1016/j.bone.2013.05.003</pub-id><pub-id pub-id-type="pmid">23680479</pub-id></mixed-citation></ref><ref id="B18"><mixed-citation publication-type="journal"><name><surname>Schmidmaier</surname><given-names>G</given-names></name><name><surname>Wildemann</surname><given-names>B</given-names></name><name><surname>Cromme</surname><given-names>F</given-names></name><name><surname>Kandziora</surname><given-names>F</given-names></name><name><surname>Haas</surname><given-names>NP</given-names></name><name><surname>Raschke</surname><given-names>M</given-names></name><article-title>Bone morphogenetic protein-2 coating of titanium implants increases biomechanical strength and accelerates bone remodeling in fracture treatment: a biomechanical and histological study in rats</article-title><source>Bone</source><year>2002</year><volume>30</volume><issue>6</issue><fpage>816</fpage><lpage>822</lpage><pub-id pub-id-type="doi">10.1016/S8756-3282(02)00740-8</pub-id><pub-id pub-id-type="pmid">12052447</pub-id></mixed-citation></ref><ref id="B19"><mixed-citation publication-type="journal"><name><surname>Li</surname><given-names>P</given-names></name><name><surname>Schwarz</surname><given-names>EM</given-names></name><article-title>The TNF-alpha transgenic mouse model of inflammatory arthritis</article-title><source>Springer Semin Immunopathol</source><year>2003</year><volume>25</volume><issue>1</issue><fpage>19</fpage><lpage>33</lpage><pub-id pub-id-type="doi">10.1007/s00281-003-0125-3</pub-id><pub-id pub-id-type="pmid">12904889</pub-id></mixed-citation></ref><ref id="B20"><mixed-citation publication-type="journal"><name><surname>Schett</surname><given-names>G</given-names></name><name><surname>Redlich</surname><given-names>K</given-names></name><name><surname>Hayer</surname><given-names>S</given-names></name><name><surname>Zwerina</surname><given-names>J</given-names></name><name><surname>Bolon</surname><given-names>B</given-names></name><name><surname>Dunstan</surname><given-names>C</given-names></name><name><surname>Gortz</surname><given-names>B</given-names></name><name><surname>Schulz</surname><given-names>A</given-names></name><name><surname>Bergmeister</surname><given-names>H</given-names></name><name><surname>Kollias</surname><given-names>G</given-names></name><name><surname>Steiner</surname><given-names>G</given-names></name><name><surname>Smolen</surname><given-names>JS</given-names></name><article-title>Osteoprotegerin protects against generalized bone loss in tumor necrosis factor-transgenic mice</article-title><source>Arthritis Rheum</source><year>2003</year><volume>48</volume><issue>7</issue><fpage>2042</fpage><lpage>2051</lpage><pub-id pub-id-type="doi">10.1002/art.11150</pub-id><pub-id pub-id-type="pmid">12847699</pub-id></mixed-citation></ref><ref id="B21"><mixed-citation publication-type="journal"><name><surname>Feghali</surname><given-names>CA</given-names></name><name><surname>Wright</surname><given-names>TM</given-names></name><article-title>Cytokines in acute and chronic inflammation</article-title><source>Front Biosci</source><year>1997</year><volume>2</volume><fpage>d12</fpage><lpage>d26</lpage><pub-id pub-id-type="pmid">9159205</pub-id></mixed-citation></ref><ref id="B22"><mixed-citation publication-type="journal"><name><surname>Lehmann</surname><given-names>W</given-names></name><name><surname>Edgar</surname><given-names>CM</given-names></name><name><surname>Wang</surname><given-names>K</given-names></name><name><surname>Cho</surname><given-names>TJ</given-names></name><name><surname>Barnes</surname><given-names>GL</given-names></name><name><surname>Kakar</surname><given-names>S</given-names></name><name><surname>Graves</surname><given-names>DT</given-names></name><name><surname>Rueger</surname><given-names>JM</given-names></name><name><surname>Gerstenfeld</surname><given-names>LC</given-names></name><name><surname>Einhorn</surname><given-names>TA</given-names></name><article-title>Tumor necrosis factor alpha (TNF-alpha) coordinately regulates the expression of specific matrix metalloproteinases (MMPS) and angiogenic factors during fracture healing</article-title><source>Bone</source><year>2005</year><volume>36</volume><issue>2</issue><fpage>300</fpage><lpage>310</lpage><pub-id pub-id-type="doi">10.1016/j.bone.2004.10.010</pub-id><pub-id pub-id-type="pmid">15780956</pub-id></mixed-citation></ref><ref id="B23"><mixed-citation publication-type="journal"><name><surname>Alblowi</surname><given-names>J</given-names></name><name><surname>Kayal</surname><given-names>RA</given-names></name><name><surname>Siqueira</surname><given-names>M</given-names></name><name><surname>McKenzie</surname><given-names>E</given-names></name><name><surname>Krothapalli</surname><given-names>N</given-names></name><name><surname>McLean</surname><given-names>J</given-names></name><name><surname>Conn</surname><given-names>J</given-names></name><name><surname>Nikolajczyk</surname><given-names>B</given-names></name><name><surname>Einhorn</surname><given-names>TA</given-names></name><name><surname>Gerstenfeld</surname><given-names>L</given-names></name><name><surname>Graves</surname><given-names>DT</given-names></name><article-title>High levels of tumor necrosis factor-alpha contribute to accelerated loss of cartilage in diabetic fracture healing</article-title><source>Am J Pathol</source><year>2009</year><volume>175</volume><issue>4</issue><fpage>1574</fpage><lpage>1585</lpage><pub-id pub-id-type="doi">10.2353/ajpath.2009.090148</pub-id><pub-id pub-id-type="pmid">19745063</pub-id></mixed-citation></ref><ref id="B24"><mixed-citation publication-type="journal"><name><surname>Feldmann</surname><given-names>M</given-names></name><name><surname>Brennan</surname><given-names>FM</given-names></name><name><surname>Elliott</surname><given-names>M</given-names></name><name><surname>Katsikis</surname><given-names>P</given-names></name><name><surname>Maini</surname><given-names>RN</given-names></name><article-title>TNF alpha as a therapeutic target in rheumatoid arthritis</article-title><source>Circ Shock</source><year>1994</year><volume>43</volume><issue>4</issue><fpage>179</fpage><lpage>184</lpage><pub-id pub-id-type="pmid">7895323</pub-id></mixed-citation></ref><ref id="B25"><mixed-citation publication-type="journal"><name><surname>Sandberg</surname><given-names>O</given-names></name><name><surname>Eliasson</surname><given-names>P</given-names></name><name><surname>Andersson</surname><given-names>T</given-names></name><name><surname>Agholme</surname><given-names>F</given-names></name><name><surname>Aspenberg</surname><given-names>P</given-names></name><article-title>Etanercept does not impair healing in rat models of tendon or metaphyseal bone injury</article-title><source>Acta Orthop</source><year>2012</year><volume>83</volume><issue>3</issue><fpage>305</fpage><lpage>310</lpage><pub-id pub-id-type="doi">10.3109/17453674.2012.693018</pub-id><pub-id pub-id-type="pmid">22616743</pub-id></mixed-citation></ref></ref-list></back></article>